Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff81a650b70e913d3b2524b45e4c7320 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
filingDate |
2021-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f140113f4482c549bd2e056ce8c5f421 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5213e399a4a8eeac83d3b1824d4927f2 |
publicationDate |
2021-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2021195300-A1 |
titleOfInvention |
Inhaled interferons for viral respiratory infections |
abstract |
Aerosolized interferon-γ is disclosed for use in preventing or treating a respiratory viral infection or pneumonia caused by a viral infection. The interferon-γ is formulated in an aqueous solution at a concentration of about 0.05 to 2.5 mg of biologically active protein per mL of solution. In an embodiment, a 2.0 mL solution containing 400 µg of interferon-γ1b is administered as an aerosol produced by a breath-enhanced jet nebulizer that can produce the aerosol with a mass median aerodynamic diameter (MMAD) of about 1.0 microns. This treatment may be effective to prevent, treat, or limit the severity of the course of infection for COVID-19, influenza, and other clinically significant viral infections. |
priorityDate |
2020-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |